WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012047093) TREATMENT OF THE SJÖGREN'S SYNDROME
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/047093    International Application No.:    PCT/NL2010/050650
Publication Date: 12.04.2012 International Filing Date: 05.10.2010
IPC:
C12N 15/113 (2010.01)
Applicants: ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM [NL/NL]; Meibergdreef 9 NL-1105 AZ Amsterdam (NL) (For All Designated States Except US).
ARTHROGEN B.V. [NL/NL]; Meibergdreef 45 NL-1105 BA Amsterdam (NL) (For All Designated States Except US).
GOTTENBERG, Jacques-Eric [FR/FR]; (FR).
MARIETTE, Xavier [FR/FR]; (FR).
DREYFUS, Patrick, A. [FR/FR]; (FR).
CHIORINI, John, A. [US/US]; (US).
VOSTERS, Jelle Lucas Guido [NL/NL]; (NL) (For US Only).
ROESCHER, Nienke [NL/NL]; (NL) (For US Only).
VERVOORDELDONK, Margarita Jacoba Bernadetta Maria [NL/NL]; (NL) (For US Only).
TAK, Paul, Peter [NL/NL]; (NL) (For US Only)
Inventors: GOTTENBERG, Jacques-Eric; (FR).
MARIETTE, Xavier; (FR).
DREYFUS, Patrick, A.; (FR).
CHIORINI, John, A.; (US).
VOSTERS, Jelle Lucas Guido; (NL).
ROESCHER, Nienke; (NL).
VERVOORDELDONK, Margarita Jacoba Bernadetta Maria; (NL).
TAK, Paul, Peter; (NL)
Agent: VAN WESTENBRUGGE, Andre; J.W. Frisolaan 13 NL-2517 JS The Hague (NL)
Priority Data:
Title (EN) TREATMENT OF THE SJÖGREN'S SYNDROME
(FR) TRAITEMENT DU SYNDROME DE SJÖGREN
Abstract: front page image
(EN)The invention provides an antisense oligonucleotide able to induce the skipping of an exon of a BAFF mRNA in order to produce a truncated form of a BAFF protein when present in a cell expressing the BAFF mRNA. This oligonucleotide may be used for treating the Sjögren's syndrome.
(FR)L'invention concerne un oligonucléotide antisens apte à induire le saut d'un exon d'un ARNm de BAFF afin de produire une forme tronquée d'une protéine BAFF, lorsqu'il est présent dans une cellule exprimant l'ARNm de BAFF. Cet oligonucléotide peut être utilisé pour le traitement du syndrome de Sjögren.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)